Abstract:Bacground: Glioblastoma (GBM) is the most common primary brain tumor, accounting for 15% of all central nervous system related tumors. Despite the aggressive standard of care treatment including chemotherapy, radiotherapy, and maximally safe surgical resection, patient outcomes are abysmal: with 95% of patients relapsing and a median overall survival of 15 months. Thus, this necessitates the rapid query for personalized therapeutics and agents that can potentiate the clinical effects of currently approved treatments. One such pathway that demonstrates aberrant functioning in cancer and is a targetable mechanism is the ubiquitin-proteosome pathway (UPP). Studies have shown that UPP related proteolysis remains constitutively active in cancer cells leading to the rapid degradation of proteins that regulate tumor suppressor genes and oncogenes. Despite robust preclinical evaluations for the usage of proteosome inhibitors against GBM, most tested proteosome inhibitors failed in phase II and III trials, indicating resistance. Methods: We conducted an unbiased genome wide CRISPR-Cas9 screen in human HAP1 cells treated with the proteosome inhibitor, Bortezomib (BTZ), to identify genes that may lead to a BTZ-resistant phenotype. We identified several genes that when perturbed, sensitized cells to BTZ including N-glycanase-1 (NGLY-1), Nuclear factor Erythroid 2-Like-1 (NFE2L1), and DNA damage inducible 1 homolog 2 (DDI2). Herein we sought to evaluate the effects of perturbing components of the proteosome rescue pathway in our Singh lab patient derived GBM cell lines by utilizing CRISPR/Cas9 knockout technology in vitro and in vivo. Results: The generation of NGLY-1, DDI2, and NFE2L1 KO cell lines demonstrated functional sensitivity to the proteosome inhibitor Marizomib (MZB) as observed through a significant reduction of the IC50 in the KO cell lines compared to a control. Functional evaluation also revealed a reduction in proliferation capacity as well as sphere formation in these genetically modified GBM lines. Ongoing in vivo work will aim to evaluate the mitigation of this resistant pathway in our NSG mouse models orthotopically transplanted with these patient derived KO cell lines. In an ongoing collaborative effort, we are working to identify and functionally assess a novel small molecule NGLY-1 inhibitor to evaluate preclinical sensitivity to MZB in our in vitro and in vivo models. Citation Format: Alisha Anand, Muhammad Vaseem Shaikh, Chirayu Chokshi, Benjamin Brakel, William Maich, Shan Grewal, Chitra Venugopal, Sheila Singh. Inhibiting elements of the proteasome recovery pathway sensitizes glioblastoma to proteasome inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5846.

Exploring Ubiquitin-specific proteases as therapeutic targets in Glioblastoma

Identification of Ubiquitin-Specific Protease 32 As an Oncogene in Glioblastoma and the Underlying Mechanisms

Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options

Targeting ubiquitin specific proteases (USPs) in cancer immunotherapy: from basic research to preclinical application

New phase therapeutic pursuits for targeted drug delivery in glioblastoma multiforme

USP7 Inhibition Induces Apoptosis in Glioblastoma by Stabilizing ARF4

Targeted therapies for Glioblastoma multiforme (GBM): State‐of‐the‐art and future prospects

Inhibition of Ubiquitin-Specific Proteases as a Novel Anticancer Therapeutic Strategy

Targeting Deubiquitinating Enzymes in Glioblastoma Multiforme: Expectations and Challenges

Role of Ubiquitination in PTEN Cellular Homeostasis and Its Implications in GB Drug Resistance

Abstract 5846: Inhibiting elements of the proteasome recovery pathway sensitizes glioblastoma to proteasome inhibitors

Clinical and translational advances in primary brain tumor therapy with a focus on glioblastoma-A comprehensive review of the literature

Targeting the Ubiquitin-Proteasome System and Recent Advances in Cancer Therapy

Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors

Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review

USP7 inhibition induces apoptosis in glioblastoma by enhancing ubiquitination of ARF4

Ubiquitin–proteasome System-Targeted Therapy for Uveal Melanoma: What is the Evidence?

Ubiquitin-specific proteases: From biological functions to potential therapeutic applications in gastric cancer

Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma

Cnsc-49. Elucidating Therapeutic Potential Of Usp1 Inhibition In Diffuse Midline Gliomas

A Multistep In Silico Approach Identifies Potential Glioblastoma Drug Candidates via Inclusive Molecular Targeting of Glioblastoma Stem Cells